Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver DiseaseBusiness Wire • 11/13/20
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3Business Wire • 11/04/20
Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock JumpsInvestors Business Daily • 09/16/20
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 ConferencesBusiness Wire • 09/08/20
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver CongressBusiness Wire • 08/28/20
IBD Rating Upgrades: Arrowhead Pharma Shows Improved Relative Price StrengthInvestors Business Daily • 08/18/20
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell CarcinomaBusiness Wire • 08/18/20
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic FibrosisBusiness Wire • 08/11/20
Arrowhead Pharmaceuticals: Now The Best Biotech Stock With Near-Term Capital Gain ProspectsSeeking Alpha • 08/11/20
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20